# US 2012/0252838 A1 · Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252838 A1
- Document ID: US20120252838A1
- Status: Published application
- Kind: A1
- Application number: 13/515,407
- Filed: 2010-12-21
- Published: 2012-10-04
- Earliest claimed: 2009-12-29
- Assignees: Eli Lilly and Company
- Inventors: Lourdes Prieto; Lorena Taboada Martinez
- Web page: https://patentgrep.com/patent/US20120252838A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein R1 is hydrogen, fluoro, chloro, or methyl; and R2 is C4-CS branched alkyl.

## Claims

### Claim 1

A compound of the formula or a pharmaceutically acceptable salt thereof
wherein
R1 is hydrogen, fluoro, chloro or methyl; and
R2 is C4-C5 branched alkyl.

### Claim 2 (depends on 1)

The compound or salt of claim 1 wherein R1 is fluoro.

### Claim 3 (depends on 1)

The compound or salt of claim 1 wherein R2 is tert-butyl.

### Claim 4 (depends on 1)

The compound or salt of claim 1 wherein
R1 is hydrogen, fluoro, chloro or methyl; and
R2 is tert-butyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, isobutyl, or 1,2-dimethylpropyl.

### Claim 5 (depends on 1)

The compound or salt as claimed in claim 1 which is (−)-3-tert-butyl-(7S)-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine.

### Claim 6 (depends on 1)

A method of treating schizophrenia, comprising administering to a patient in need thereof an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

A process for preparing a compound of formula I, or a pharmaceutically acceptable salt thereof, comprising
A) for a compound of formula I,
wherein
R1 is hydrogen, fluoro, chloro or methyl; and
R2 is C4-C5 branched alkyl;
condensing of a compound of formula VII with a compound of formula II wherein R3 is C1-C3 alkyl
or alternatively
B) for a compound of formula I, condensing an R2-acyl hydrazine with a compound of formula III wherein X is O or S, and R4 is C1-C3 alkyl.
whereafter, when a pharmaceutically acceptable salt of the compound of formula I is desired, it is obtained by reacting a basic compound of formula I with a physiologically acceptable acid.
